REFERENCES

1. Paridaen, J. T.; Huttner, W. B. Neurogenesis during development of the vertebrate central nervous system. EMBO Rep. 15, 351-64 (2014).

2. Thor, S. Indirect neurogenesis in space and time. Nat. Rev. Neurosci. 25, 519-34 (2024).

3. Chen, L. et al. Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases. Signal Transduct. Target. Ther. 10, 31 (2025).

4. Tao, L. et al. Slc22a17 governs postnatal neurogenesis by maintaining the iron homeostasis in hippocampus. Nat. Commun. 16, 11117 (2025).

5. Zhao, J.; Wang, Y.; Tao, L.; Chen, L. Iron transporters and ferroptosis in malignant brain tumors. Front. Oncol. 12, 861834 (2022).

6. Faust, T. E.; Gunner, G.; Schafer, D. P. Mechanisms governing activity-dependent synaptic pruning in the developing mammalian CNS. Nat. Rev. Neurosci. 22, 657-73 (2021).

7. Wang, Z. et al. Ferroplasticity drives social isolation-induced anxiety via a ventral hippocampal iron-α-synuclein axis. Cell Metab. (2026). (Epub ahead of print).

8. Ayton, S.; Moreau, C.; Devos, D.; Bush, A. I. Iron on trial: recasting the role of iron in neurodegeneration. Brain 148, 4241-7 (2025).

9. Levi, S.; Finazzi, D. Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms. Front. Pharmacol. 5, 99 (2014).

10. Du, W.; Tang, B.; Liu, S.; Zhang, W.; Lui, S. Causal associations between iron levels in subcortical brain regions and psychiatric disorders: a Mendelian randomization study. Transl. Psychiatry 15, 19 (2025).

11. McCarthy, E. K.; Murray, D. M.; Hourihane, J. O. B.; Kenny, L. C.; Irvine, A. D.; Kiely, M. E. Behavioral consequences at 5 y of neonatal iron deficiency in a low-risk maternal-infant cohort. Am. J. Clin. Nutr. 113, 1032-41 (2021).

12. Ru, Q.; Li, Y.; Chen, L.; Wu, Y.; Min, J.; Wang, F. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct. Target. Ther. 9, 271 (2024).

13. Shapiro, J. S. et al. Iron drives anabolic metabolism through active histone demethylation and mTORC1. Nat. Cell Biol. 25, 1478-94 (2023).

14. Devos, D. et al.; a Parkinson’s disease study group. Therapeutic modalities of deferiprone in Parkinson’s disease: SKY and EMBARK studies. J. Parkinsons. Dis. 15, 72-86 (2025).

15. Friedrich, I. et al. Cell specific quantitative iron mapping on brain slices by immuno-µPIXE in healthy elderly and Parkinson’s disease. Acta Neuropathol. Commun. 9, 47 (2021).